Akamis Bio
Clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors.
$60M Series A ·
Led by Sedgwick Yard · Source: fundraisingfox.com
Funding history ↓Signals
Akamis Bio | 5128 days from X account to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $60M | fundraisingfox.com |
Timeline
- Website created
- X account created
Founders and team
AC
Andrew Coats FounderJB
John Beadle FounderKF
Kerry Fisher FounderHD
Howard Davis Chief Executive OfficerPM
Priya Mande Chief Operating Officer and U.K. President- TLTom Lillie Chief Medical Officer
Acquisitions
| Acquired company | Price | Announced |
|---|---|---|
| HHybrid BioSystems | Not disclosed publicly | Date not given |
Investors
AARCH Venture Partners
BBristol-Myers Squibb
IImperial Innovations
IIP Group
LLundbeckfonden Ventures
PParker Institute for Cancer Immunotherapy
SSalica
SSedgwick Yardlead investor
WWestlake Village BioPartners
WWoodford Investment Management
Companies like Akamis Bio
IIDRx$120M Series B+ · Aug 2024
AAlpha-9 Oncology$175M Series B+ · Oct 2024
RRondo Therapeutics$67M Series A · Mar 2022
33T Biosciences$40M Series A · Aug 2022
TTiltbio$25M Series B+ · May 2025SSpecific Biologics$35M Series A · Nov 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/akamis-bio (get a free API key).